you was we hope February. for are safe. joining and call is it in everybody. earnings And staying I our us certainly Ami, the today, when and good Thanks did afternoon, than world your and Thanks, back families different quite
So quarter net terms of largely in of which and obviously we bottle. first volumes below environment. ahead COVID-XX are In today, the per the pandemic; in unaffected we'll back slightly of expectations on at focus our is quarter then short, the performance and – seeing terms look start first of what expectations our we'll XXXX, current by in internal our was revenue
of XXXX increase where shipment of for the just sequential XXXX revenues decline over X% $XX QX. first we of generated the the totaled XX% in over a a QX sequential we wholesale XXXX, experienced quarter in this first versus year, fourth Net of million. unit XXXX, of quarter quarter Unlike versus volumes
strongly. very, started The off first quarter performance very XXXX
XXXX various states the especially an that, at up, withdraw ones and as of open as governmental predicting the we opening down response pandemic, In of up year spite marketplace full it's the our the first or when decided rest made to we exited the year previous brought guidance we the COVID-XX impact slowly. certainly to Uncertainty to uncertain doing in volumes the other declining year. with exercise, quarter now so scrip of look the
year – guidance to it's it's all. So, tough certainly a provide any at
expenses, see did by that pass February out-of-pocket experience, most et the we cetera, March. entered healthy pharma we softness volume caused January and increases in and increases as volume deductibles we Once companies seasonal usually
basically using MOST in eye pick from that reversed for care getting increases And largest for this in quarter up declining, in saw activity as it – uptick saw flat where You might the both prescription towards positive trial momentum part the expected [indiscernible] a QX you which was meaningfully Rocklatan. Rhopressa. we data the message that we be building to we the recall to as our volumes and our Rhopressa gave result we professionals of or year guidance of appear also, out, and
we at is on net the did remember, exposure net our expect per at in bottle as per remain coming over concerned, XXXX cap $XX in bottle with net far to As per full coming where, year heels revenue experience coverage revenue bottle of – revenue the XXXX in $XXX.
other shift managed volumes had than we care unit was mix larger D, coverage there Medicaid and a Medicare in As anticipated. grew and QX, through government Part to our payers
other companies There's has certainly been like in, governance kicking because Part on unemployment but increased lower been not certainly programs been a coverage, prices. of usage the increasing; the in seen have commercial more talk D. You've utilization cards. the systems much about decrease an full see are we Medicaid, which side, certainly, co-pay us, cetera, obviously, do et our for commercial, And
programs. effective a our considerably. with formularies recall of come We coverage would the that, might that last providers You volumes A implemented portion Part coverage, January health on-boarding contracting new between rebated lag fact, over discussions X, D and those with in of the various We year. stated time. discussed and was Medicare increased formulary within insurance formulary the
the same, the At and this lives one contracted formulary and coverage the which perhaps point, excellent news. is are percentages
we patients, this X the part rebate correspondingly – as and again, for that underlying for D Part for from prescriptions the levels As co-pays demonstrable started increase volume, providing we new analyzed which closed definition, by Medicare a allows covers by formulary and higher result. greater-than-expected mix, higher lower the a saw quarter in that in mix, books payer January
that, per at net revenue With our in bottle came $XX.
to plus commercial than coverage requirement all of rebated of a net that, top the are relative on accounts funding the that lower steeply government of in resulting what per revenues has bottle the know, accounts, commercial the D you experienced on business. Medicare Part As we more side
disease Part well growth Of volume particular, side, Medicare ultimately the the volumes. of and for aging in is should course, a glaucoma on D seeing bode future
experienced amounted less there $X.X than we net that net in in the QX. million reference, QX that we revenues out difference that For benchmark revenues versus to before $XX for $XX between had the
have appear extended in to populations, XX-day supply the We favoring associated also noticing been elderly those time as be plans, with increases over along supply.
is actually trend possible COVID-XX glaucoma mail-order to upside they their needing current continues, broader where recognizing ratio below patients in some and that without the leave taking are that homes. XX-day If there. of more Therefore, eye advantage bottles have that run, drops may is beneficial of we their plans, to the the getting us of currently greater to long prove that It situation, the of convenience our may see with market. scrip the this more
launch – gained Effective and Rocklatan We've great Rhopressa Part we finally one for as that our it. a position not of we in – was expected, offers, the May to on on was time both was that it nation. the Rhopressa, the have year-end of of we Further get formulary coverage, not coverage steep. good rebate some working very largest was wouldn't from too At Medicare the there news. XXXX were accept players since for that this been so call, X, D they
And because we day, that getting deal you strategy. much we up as prior ultimately had at worked we than the end the of And better a instead ended strategy can imagine, authorization expected. pursued a
for from XX%, And subsidy for now on Part of Rhopressa, patients with Our Rocklatan. is to from an XX% of up the now up bringing Medicare Rocklatan low-income affordable D XX% XX% Part over D co-pays. There's XX%. top coverage there's up XX%. XX%, Rocklatan is extra XX% Medicare Plus,
more driving in these with Commercial In increases volumes. the up much it earlier, case, of coverage future XX% than Tom and a remains Rhopressa other, bit independent timing very, to environment, to I in well. although magnitude the strong open Rocklatan as XX% still some, normal faster carry for the especially, commercial a obviously and as be talks are states is almost this coverage difficult about others very determine will up, coverage talk quite about that environment, coverage weight again, he That's little side. for of in a the would when opening each and mentioned bit as
D should clearly run, on the that will as increased of is my going greater more greater getting over our forward, coverage That coverage. for thing benefit we're be the bottle revenues for, somewhat volumes is long weigh net in volume offset part One the this Medicare per looking sure while meaningful. potential Part mind
Changing it gears Tom for our important other before commercial on touch over to turn to I initiatives. like briefly further insight, I'd
Avizorex. to expect our this for in half continue of dry eye second of we obtained We commence that IIb to Phase late the acquisition year XXXX trial candidate through our product the
various currently We looking work, conducting at concentrations. are toxicology
year, we and know, open off once enrollment Although programs it as million dry XX see hopeful of very in we are them up very, sufferers and treated, may United these we are predict, that only the with hard states about X the million it States, in eye later get over many you in rapid to could ground. be the clinical
virtual PMDA with to recommended III very with we being a about clarity had so month in that well we approach meeting to Japan, a very, The what the good went news it's added for ago. with see. meeting Phase and very the programs, much For line or expected
half We are year. – Rhopressa preparing to the partnership have we And of in also the opportunities. trial we for commencement in at continued this time, of Japan explore same in Phase second III
in dexamethasone AR-XXXXX, and trial release be is insert, expect II for the for study continue, this our kinase top clinical of that which will Rho retina a later do our clinical XXXX, sustained programs year. data the of addition is to which enrollment first completing for we line and Our Phase end by our AR-XXXX, in-human inhibitor,
because trials do regimens is track. that and doc retina they our part many requirement, the those. remain with seeing And without patients are are We injection your generally open can't they on the that, a staying in have offices on of
our decide As candidates XXXX, expect I we but best not success. dry best eye of data programs end do the of have chances product on last from our with product the clinical proceed out our ultimately retina for clinical adequate multiple call, and with to commercial pointed to our only how by
X top end awaited last is very of expected to we enrolling X Roclanda close XXXX. our line for data The Europe, Mercury by Europe. data We're Mercury from getting the For potentially our patient.
again, XXXX. are either in by So seen is later up that this sometime early finishing the haven't year authorities we that hope slowdown Roclanda we European approved or as major We XXXX a to hear program.
products glaucoma X commercial Mercury We our in the and the in Europe for prospects will to opportunity data the on continue the region. based commercial evaluate
Finally, on COVID-XX.
efforts schedules in regimens hygiene and accordance not feasible done patients. remotely, to not our technology employees, X our are care priority safety the remains and ample and Number only the securely. employees from and implemented work support have have Our local safety since health with safely home, we professionals it and have personal health of to we our and those Majority of Where flexible but is working instituted regulations.
being example, the that an Athlone normally for of would U.S., to As approved very get few Rocklatan months. staffed commercial that working hoping Rocklatan manufactured be by batch able around in Rocklatan, that on here next the over production January XX productive. site. the was own we'll complete commercial which our be we're for out our currently able in plant, XX the distribution the in is of in they're marketplace the to out our We've so first And facility of been of U.S. employees
In the prior addition of that, for been team Rhopressa. the approval preparing has to supplement
that in that So, trial And fact, to Phase first using there. clinical able Rocklatan that last both III hope of that in the out least, last be we'll and material in facility. approved, be for but our produced manufacture get by we'll not and Japan of batch year-end, recently, week, the Ireland to actually Rhopressa the we in team just so
supply inventory do We point And sources product with chain live, our goods, inventory and issues no years over coming Irish manufacturing to have we starting and an is we over month three plant believe date. ongoing. of of have from. and production API of that we six now From have view, can finished material we three finished now had choose
seeing we're to of the position to Tom cover glaucoma that perspectives a I'd and the the like now to is over turn on to perspective. call What our as landscape his from result current environment in what do
So Tom?
